Tag: ML7710

Near-infrared Photoimmunotherapy Targeting Canine Mammary Tumors: Comparative Oncology for Overcoming Human Breast Cancer

Scientific papers / 690 nm, breast cancer, in vitro, in vivo, ML7710, NIH, Photoimmunotherapy, tumor / July 29, 2026

Published in: Anticancer Research Authors: Motofumi Suzuki, Aki Furusawa, Hiroshi Yamamoto, Ko Kitamura, Makoto Kano, Miyu Kano, Seiichiro Takao, Yukinari Kato, Amy K. Leblanc, Peter L. Choyke, Hisataka Kobayashi

Near-infrared Photoimmunotherapy Targeting Canine Mammary Tumors: Comparative Oncology for Overcoming Human Breast Cancer Read More »

Mirabody–IR700: A novel EGFR-targeting platform for photoimmunotherapy

Scientific papers / 690 nm, cancer, cytotoxicity, in vitro, in vivo, IR700, ML7710, Photoimmunotherapy, research, tumor / July 29, 2026

Published in: Biomedicine & Pharmacotherapy Authors: Citra R.A.P. Palangka, Motofumi Suzuki, Ayaka Kanai, Azusa Nitta, Junichi Takagi, Hirofumi Hanaoka

Mirabody–IR700: A novel EGFR-targeting platform for photoimmunotherapy Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – June 2026

Laser-sharp Research / antibiotic resistance, antimicrobial, antimicrobial therapy, appendicitis, disinfection, in vitro, in vivo, intra-abdominal infection, laparoscopic surgery, laser therapy, laser-sharp research, methylene blue, ML7710, PDT, pediatric surgery, perforation, Photodynamic therapy, Photoimmunotherapy, photomedicine, translational research / June 22, 2026

Research teams led by Dr. Timothy Baran and Dr. Nicole Wilson investigated laser-activated methylene blue therapy for perforated appendicitis. Using the ML7710 laser system, the study demonstrated a feasible and safe resistance-independent antimicrobial treatment approach.

Modulight Spotlights: LASER-SHARP RESEARCH – June 2026 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – April 2026

Laser-sharp Research / 689 nm, cancer, immunotherapy, IR700, laser therapy, laser-sharp research, ML7710, peptides, Photoimmunotherapy, targeted therapies, tumor / April 27, 2026

Modulight Spotlights: LASER-SHARP RESEARCH – April 2026 This month we are pleased to highlight new interesting article by Naoya Kondo and the team at Kansai Medical University in Japan. They developed a cancer cell-targeted photoimmunotherapy compound consisting of IR700 photoabsorber conjugated to bicyclic peptide. Use of small peptide could speed drug clearance from the body

Modulight Spotlights: LASER-SHARP RESEARCH – April 2026 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – March 2026

Laser-sharp Research / chemo resistance, in vitro, in vivo, laser-sharp research, ML7710, ML8500, National Cancer Institute, ovarian cancer, peritoneal carcinoma, photoimmunoconjugates, Photoimmunotherapy, targeted therapies, University of Maryland / March 12, 2026

Modulight Spotlights: LASER-SHARP RESEARCH – March 2026 The development of chemoresistance presents a major challenge in treating peritoneal metastasis, which often occurs in advanced ovarian cancer. To tackle this, Kaitlyn Moore and teams at University of Maryland and National Cancer Institute evaluated photoimmunotherapy as a solution to inhibit a drug efflux pump on cancer cells

Modulight Spotlights: LASER-SHARP RESEARCH – March 2026 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – February 2026

Laser-sharp Research / antibodies, Cancer therapy, laser therapy, laser-sharp research, ML7710, next generation therapies, peptides, Photoimmunotherapy, tumor / February 27, 2026

Modulight Spotlights: LASER-SHARP RESEARCH – February 2026 This month, we are highlighting promising work by Professor Hirofumi Hanaoka’s team at Kansai Medical University, Photo-ImmunoTherapy Research Institute. They developed a novel peptide-based photoimmunotherapy drug that targets PD-L1, which is expressed on many types of cancer cells. Preclinical experiments showed significant suppression of tumor growth and an

Modulight Spotlights: LASER-SHARP RESEARCH – February 2026 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – October 2025

Laser-sharp Research / breast cancer, immunotherapy, laser-sharp research, ML7710, myeloma, oral cancer, Photoimmunotherapy, preclinical, T cells / October 29, 2025

This month we are highlighting exciting findings by S. Takao et al. from Hisataka Kobayashi’s lab at the National Cancer Institute, NIH. Published in Cancer Letters, the study shows that near-infrared photoimmunotherapy can destroy cancer cells by targeting intercellular adhesion molecule-1.

Modulight Spotlights: LASER-SHARP RESEARCH – October 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – September 2025

Laser-sharp Research / cancer, immunotherapy, in vitro, in vivo, laser-sharp research, ML7710, noveltherapies, Photoimmunotherapy, targeted therapy / September 2, 2025

Published in journal Cancer Medicine, the study shows that the therapeutic effect of photoimmunotherapy is highly dependent on the used light irradiation conditions. Application of the ML7710 medical laser at different durations and powers resulted in highest anti-tumor effect with increased light dose but lowering fluence rate below what is currently used in clinic.

Modulight Spotlights: LASER-SHARP RESEARCH – September 2025 Read More »

Interleukin 15 (IL15)-based near-infrared photoimmunotherapy

Scientific papers / 690 nm, in vitro, in vivo, interleukin15, IR700, light activation, ML7710, National Cancer Institute, NIH, NIR, Photoimmunotherapy, PIT, tumor / August 31, 2025

Published in: Cancer Immunology, Immunotherapy Authors: Motofumi Suzuki, Aki Furusawa, Hiroshi Yamamoto, Makoto Kano, Miyu Kano, Seiichiro Takao, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi

Interleukin 15 (IL15)-based near-infrared photoimmunotherapy Read More »